Pfizer Raises 2026 Revenue Guidance Amid Strong Growth in Acquired Products

During its third-quarter 2026 earnings call, Pfizer (PFE) raised its full-year revenue guidance to a range of $62 billion to $64 billion. The company reported significant momentum from newly launched and acquired products, which achieved 32% operational revenue growth in the quarter, helping to buffer against upcoming patent expirations on legacy blockbuster drugs. To protect margins during this transition period, Pfizer is implementing aggressive productivity initiatives aimed at achieving $7.2 billion in net cost savings by the end of 2026. Management's long-term strategy focuses on reinvesting these savings into oncology pipelines and obesity treatments, targeting a high single-digit revenue compound annual growth rate (CAGR) between 2028 and 2033.

18 articles from 4 sources · updated

Coverage